Cambridge Investment Research Advisors’s AllianzIM U.S. Equity Buffer10 Feb ETF FEBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$355K Hold
8,625
﹤0.01% 3060
2026
Q1
$323K Buy
8,625
+1,908
+28% +$73.2K ﹤0.01% 3220
2025
Q4
$256K Hold
6,717
﹤0.01% 3361
2025
Q3
$249K Sell
6,717
-737
-10% -$26.6K ﹤0.01% 3292
2025
Q2
$262K Hold
7,454
﹤0.01% 3093
2025
Q1
$244K Buy
+7,454
New +$251K ﹤0.01% 3052
2024
Q2
Sell
-6,604
Closed -$204K 3360
2024
Q1
$204K Buy
+6,604
New +$197K ﹤0.01% 3009
2023
Q2
Sell
-8,650
Closed -$219K 3213
2023
Q1
$219K Buy
+8,650
New +$215K ﹤0.01% 2753

Other funds holding FEBT

Cambridge Investment Research Advisors's FEBT Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its AllianzIM U.S. Equity Buffer10 Feb ETF (FEBT) position steady in Q2 2026 at 8,625 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Cambridge Investment Research Advisors first reported a position in FEBT in Q1 2023 and has held it in 8 quarters since. 14 funds tracked by Wall St. Rank hold FEBT as of Q2 2026.

  • Cambridge Investment Research Advisors held 8,625 shares of AllianzIM U.S. Equity Buffer10 Feb ETF worth $355K as of Q2 2026.
  • Cambridge Investment Research Advisors left its AllianzIM U.S. Equity Buffer10 Feb ETF share count unchanged in Q2 2026.
  • AllianzIM U.S. Equity Buffer10 Feb ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3060 holding.
  • Cambridge Investment Research Advisors first reported a position in AllianzIM U.S. Equity Buffer10 Feb ETF in Q1 2023 and has held it in 8 quarters since.
  • 14 funds tracked by Wall St. Rank held AllianzIM U.S. Equity Buffer10 Feb ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.